<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502811</url>
  </required_header>
  <id_info>
    <org_study_id>17-518</org_study_id>
    <nct_id>NCT03502811</nct_id>
  </id_info>
  <brief_title>The MitraClip® EXPAND Study</brief_title>
  <official_title>A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip® Devices (EXPAND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evalve</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evalve</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world
      Experience of Performance and Safety for the Next Generation of MitraClip Devices) is
      designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR
      System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data collected in this study will be used to evaluate device outcomes and characterize
      trends in patient selection for MitraClip therapy in contemporary real-world use. Clinical
      outcomes and Echocardiographic measures will be assessed in the context of historical data.

      The MitraClip EXPAND Study will be conducted on commercial MitraClip NTR System and MitraClip
      XTR System that have received CE Mark and/or FDA approval as required.

      Up to 1,000 subjects at a maximum of 60 sites in Europe and the US will be in the MitraClip
      EXPAND Study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Major Adverse Events (MAE)</measure>
    <time_frame>up to 30 Days</time_frame>
    <description>MAE is defined as a composite of all-cause Death, Myocardial Infarction, Stroke, or non-elective Cardiovascular (CV) surgery for device related complications (CEC adjudicated).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MR Reduction to ≤2+</measure>
    <time_frame>At 30 days</time_frame>
    <description>MR Severity of 2+ or less at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No of participants with APS</measure>
    <time_frame>Up to 10 Days</time_frame>
    <description>Acute Procedural Success (APS) defined as successful implantation of the MitraClip® device with resulting MR severity of 2+ or less on discharge Echocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No of participants with ADS</measure>
    <time_frame>Up to 10 Days</time_frame>
    <description>Acute Device Success defined as successful implant of the MitraClip device without the occurrence of a Device-Related Complication (including device embolization, Single Leaflet Device Attachment (SLDA), bleeding, or perforation) through discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR Reduction to ≤1+</measure>
    <time_frame>At 30 Days</time_frame>
    <description>MR Reduction to ≤1+ at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>up to 30 Days</time_frame>
    <description>All Cause Mortality Through 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>up to 6 Months</time_frame>
    <description>All Cause Mortality Through 6 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>up to 12 Months</time_frame>
    <description>All Cause Mortality Through 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalization</measure>
    <time_frame>up to 30 Days</time_frame>
    <description>Heart Failure Hospitalization Through 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalization</measure>
    <time_frame>up to 6 Months</time_frame>
    <description>Heart Failure Hospitalization Through 6 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalization</measure>
    <time_frame>up to 12 Months</time_frame>
    <description>Heart Failure Hospitalization Through 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of MAE</measure>
    <time_frame>At 30 Days</time_frame>
    <description>Occurrence of Major Adverse Events (MAE) as defined in the protocol at 30 Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of MAE</measure>
    <time_frame>At 6 Months</time_frame>
    <description>Occurrence of Major Adverse Events (MAE) as defined in the protocol at 6 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of MAE</measure>
    <time_frame>At 12 Months</time_frame>
    <description>Occurrence of Major Adverse Events (MAE) as defined in the protocol at 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Related Complications</measure>
    <time_frame>Up to 10 Days</time_frame>
    <description>Device Related Complications as defined in the protocol at Discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Related Complications</measure>
    <time_frame>Up to 30 Days</time_frame>
    <description>Device Related Complications as defined in the protocol at 30 Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Related Complications</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>Device Related Complications as defined in the protocol at 6 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Related Complications</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Device Related Complications as defined in the protocol at 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class improvement</measure>
    <time_frame>Zero and 30 Days</time_frame>
    <description>Difference Between NYHA Class at Baseline and 30Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class improvement</measure>
    <time_frame>Zero and 12 Months</time_frame>
    <description>Difference Between NYHA Class at Baseline and 12 Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Zero and 30 Days</time_frame>
    <description>Difference Between QOL at Baseline and 30 Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Zero and 12 Months</time_frame>
    <description>Difference Between QOL at Baseline and 12 Months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>MitraClip NTR/XTR System</arm_group_label>
    <description>Percutaneous mitral valve repair using the MitraClip NTR and XTR system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip NTR/XTR System</intervention_name>
    <description>Percutaneous mitral valve repair using the MitraClip NTR/XTR system.</description>
    <arm_group_label>MitraClip NTR/XTR System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include patients who will undergo commercial procedures with the MitraClip®
        NTR System and/or MitraClip® XTR System after required approval of the device is obtained.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who give consent for study procedure

          2. Subjects eligible to receive the MitraClip per the current approved indications for
             use

          3. Subjects with Symptomatic MR (≥3+)

        Exclusion Criteria:

        1. Subjects participating in another clinical study that may impact the follow-up or
        results of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Saibal Kar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars Sinai, Los Angeles CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Francesco Maisano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Ornelas</last_name>
    <phone>408-306-7436</phone>
    <email>leslie.ornelas@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Tims</last_name>
    <phone>4089480736</phone>
    <email>erin.tims@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saibal Kar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saibal Kar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Sorajja</last_name>
    </contact>
    <investigator>
      <last_name>Paul Sorajja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael J Rinaldi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael J Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Lim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Scott Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Univsität München (LMU)/ Grosshadern</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Hausleiter</last_name>
    </contact>
    <investigator>
      <last_name>Jörg Hausleiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts Medizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhinela</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph Stephan von Bardeleben</last_name>
    </contact>
    <investigator>
      <last_name>Ralph Stephan von Bardeleben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Lurz</last_name>
    </contact>
    <investigator>
      <last_name>Philipp Lurz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitares Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Schafer</last_name>
    </contact>
    <investigator>
      <last_name>Ulrich Schafer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Colombo</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Colombo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Denti</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Denti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>Milano</city>
        <state>Lombard</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Bedogni</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Bedogni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Ferrarotto Alessi</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmello Grasso</last_name>
    </contact>
    <investigator>
      <last_name>Carmello Grasso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Windecker</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Windecker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Maisano</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Maisano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MitraClip</keyword>
  <keyword>MitraClip NTR</keyword>
  <keyword>MitraClip XTR</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

